Sciex and Pressure BioSciences Address Complex Sample Preparation
Sciex (Framingham, Massachusetts, USA) has announced a co‑marketing agreement with Pressure BioSciences, Inc. (South Easton, MA, USA), which aims to address the challenges arising in complex sample preparation.
Sciex (Framingham, Massachusetts, USA) has announced a coâmarketing agreement with Pressure BioSciences, Inc. (South Easton, MA, USA), which aims to address the challenges arising in complex sample preparation. This joint venture will enable Sciex to market a complete service to increase the depth, breadth, and reproducibility of protein extraction, digestion, and quantitation in all tissue types, including challenging samples like tumours.
“Advancing precision medicine through the ability to reproducibly quantitate thousands of proteins in large clinical sample cohorts is of the utmost importance to both academic and clinical research labs,” said Mark Cafazzo, Director of Academic and Clinical Research Business at Sciex.
Through combining technological knowledge Pressure BioSciences, Inc. and Sciex hope to help “scientists address the sample preparation challenges they face every day, especially when working with difficult tissue samples.”
Mr. Cafazzo continued: “The net result is more comprehensive protein quantitation from complex samples, increased productivity, and higher quality results. This is an exciting step forward for the field of proteomics, one that offers the potential to make a great and lasting impact on the quality of human life.”
Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc., commented: “By combining [our] methods with Sciex’s expertise and successful history in mass spectrometry system solutions, clinical researchers will be equipped to make major leaps forward in proteomic analysis, over the current limitations of traditional methods.”
Sciex and Pressure BioSciences, Inc. hope this deal will significantly expand the footprint of MS-based quantitation workflows in clinical research settings worldwide.
For more information please visit www.sciex.com and www.pressurebiosciences.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
